| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651048 | American Heart Journal | 2018 | 26 Pages |
Abstract
PCI occurred infrequently during follow-up. Most patients on study drug at the time of PCI remained on study drug in the peri-PCI period; 19% continued the study drug without interruption. Antiplatelet therapy use post-PCI was variable, although most patients received DAPT. Additional data are needed to guide the use of antithrombotics in patients undergoing PCI.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
David MD, W. Schuyler MD, Matthew W. MD, Daniel M. MS, Lars MD, PhD, Basil S. MD, Freek W.A. MD, PhD, Dragos MD, PhD, M. Cecilia MD, Sigrun MD, PhD, Kurt MD, Alexander MD, PhD, Christopher B. MD, Renato D. MD, PhD, MHS, John H. MD, MHS,